Literature DB >> 7433320

Some cardiovascular problems with disopyramide.

S J Warrington, J Hamer.   

Abstract

Five patients with apparent adverse cardiovascular effects of disopyramide are reveiwed. Attention is drawn to the following problems. (1) A vagolytic effect may produce a sinus tachycardia with wide QRS complexes due to aberrant conduction or intraventricular block superficially resembling a ventricular tachycardia, or may allow increased transmission of an atrial tachycardia or atrial flutter to the ventricles by improving atrio-ventricular conduction. (2) Although the vagolytic effect is helpful in increasing sinus rate in patients with sinus node disease, disopyramide may lead to bradycardia and asytolic cardiac arrest, and should not be used without a demand pacemaker. (3) Dangerous ventricular arrhythmias may be provoked in susceptible subjects, as with quinidine. (4) Rapid intravenous injection may produce transient toxic effects before the drug is distributed. The rate of injection as a loading dose for prophylaxis should be slower (2 mg/kg in 15 min) than for the urgent conversion of a resistent tachycardia (2 mg/kg in 5 min). Although disopyramide seems less toxic than quinidine, caution is advised, as over-enthusiastic application of disopyramide, particularly with rapid intravenous injection, might tend to bring a useful new agent into disrepute.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7433320      PMCID: PMC2425888          DOI: 10.1136/pgmj.56.654.229

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  16 in total

1.  [Letter: Syncopes through the inversion of points in connection with the absorption of disopyramide].

Authors:  B Casedevant; D Sabaut; J Clementy; M Dallocchio
Journal:  Nouv Presse Med       Date:  1975-10-04

2.  Correlation of disopyramide pharmacokinetics with efficacy in ventricular tachyarrhythmia.

Authors:  R E Rangno; W Warnica; R I Ogilvie; J Kreeft; E Bridger
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

3.  Torsade De Pointes, an atypical ventricular tachycardia.

Authors:  D M Krikler; P V Curry
Journal:  Br Heart J       Date:  1976-02

4.  Letter: Sinus recovery time after disopyramide phosphate.

Authors:  L Seipel; G Breithardt
Journal:  Am J Cardiol       Date:  1976-06       Impact factor: 2.778

5.  Disopyramide phosphate: pharmacokinetic and pharmacologic relationships of a new antiarrhythmic agent.

Authors:  R E Ranney; R R Dean; A Karim; F M Radzialowski
Journal:  Arch Int Pharmacodyn Ther       Date:  1971-05

6.  Disopyramide phosphate: clinical efficacy of a new oral antiarrhythmic drug.

Authors:  L A Vismara; D T Mason; E A Amsterdam
Journal:  Clin Pharmacol Ther       Date:  1974-08       Impact factor: 6.875

7.  [Our first clinical test of disopyramide (H 3292) on cardiac rhythm disorders].

Authors:  J Desruelles; A Gerard; P Ducatillon; A Herbaux
Journal:  Therapie       Date:  1967 Jul-Aug       Impact factor: 2.070

Review 8.  Cardiac effects of disopyramide.

Authors:  P Danilo; M R Rosen
Journal:  Am Heart J       Date:  1976-10       Impact factor: 4.749

9.  Normal myocardial contractile state in the presence of quinidine.

Authors:  W Markiewicz; R Winkle; G Binetti; R Kernoff; D C Harrison
Journal:  Circulation       Date:  1976-01       Impact factor: 29.690

10.  Efficacy of disopyramide phosphate in the treatment of refractory ventricular tachycardia.

Authors:  L A Vismara; Z Vera; R R Miller; D T Mason
Journal:  Am J Cardiol       Date:  1977-06       Impact factor: 2.778

View more
  2 in total

Review 1.  Adverse effects of class I antiarrhythmic drugs.

Authors:  J Caron; C Libersa
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

Review 2.  Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.

Authors:  R N Brogden; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.